Form 4: PharmaCyte CEO Boosts Stake with $80K Stock Purchases

PharmaCyte Biotech's CEO and President, Joshua Silverman, increased his direct beneficial ownership of common stock by 100,000 shares through open market purchases totaling approximately $80,000 in early January 2026.

Summary

• Joshua Silverman, CEO and President of PharmaCyte Biotech, Inc. (PMCB), acquired a total of 100,000 shares of common stock through open market purchases.
• The purchases occurred over three consecutive days: 30,000 shares on January 5, 2026, 30,000 shares on January 6, 2026, and 40,000 shares on January 7, 2026.
• The shares were acquired at prices ranging from $0.7831 to $0.8329 per share, totaling approximately $80,476.
• Following these transactions, Silverman's direct beneficial ownership increased to 416,250 shares.
• Silverman also holds an indirect beneficial ownership of 50,000 shares through JNS Holdings Group LLC.
• A Power of Attorney was filed, authorizing specific individuals from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to execute and file Section 16 forms on Silverman's behalf.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by the CEO, indicating strong confidence in the company's future prospects and valuation.

Positives

• The CEO and President, Joshua Silverman, increased his direct beneficial ownership, signaling confidence in the company's future prospects.
• The open market purchases demonstrate a personal investment by top management, aligning their interests with those of shareholders.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Joshua Silverman holds indirect beneficial ownership of 50,000 shares through JNS Holdings Group LLC.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and belief in the company's value, potentially boosting investor confidence.
• The market may react positively to the news of insider buying, potentially influencing the company's stock price.

Key Dates

Recommendation

The CEO's substantial open market purchases of company stock signal strong confidence in PharmaCyte Biotech's future. Insider buying often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for investors.

Keywords

PharmaCyte Biotech, PMCB, Insider Trading, Stock Purchase, CEO, Director, Beneficial Ownership, Form 4